Table 2.

Comparison of pain, VA, and CMT values and their changes during the study follow-up among different injection sites

	Total	Injection site				p-Valuea
		IN	IT	SN	ST
Pain	2.9 ± 2.2	3 ± 2.3	3 ± 2.1	1.5 ± 1.7	4 ± 2	<0.001
Pre-injection BCVA (logMAR)	0.64 ± 0.35	0.61 ± 0.37	0.65 ± 0.41	0.6 ± 0.31	0.69 ± 0.3	0.022
Post-injection BCVA (logMAR)	0.49 ± 0.26	0.42 ± 0.27	0.53 ± 0.24	0.48 ± 0.25	0.5 ± 0.27	0.008
Change of BCVA	−0.22 ± 0.27	−0.24 ± 0.22	−0.31 ± 0.32	−0.19 ± 0.26	−0.2 ± 0.26	0.007
Within p-valueb		<0.001	<0.001	<0.001	<0.001
Pre-injection CMT	447 ± 194	417 ± 129	452 ± 152	461 ± 158	471 ± 341	0.071
Post-injection CMT	277 ± 212	252 ± 41	294 ± 72	277 ± 386	279 ± 49	0.828
Change (µm) CMT	−170 ± 284	−138 ± 91	−124 ± 67	−182 ± 349	−195 ± 338	0.445
Within p-valueb		<0.001	<0.001	<0.001	<0.001

IN inferonasal, IT inferotemporal, SN superonasal, ST superotemporal, BCVA best-corrected visual acuity, CMT central macular thickness

^ap-Values are based on ANOVA

^bp-Values are based on paired t-test